Lantern Pharma Inc.

LTRN

US51654W1018

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 06/07/2024 am IST			5-day change	1st Jan Change
4.38 ^USD	+2.10%		-6.21%	+2.34%

01/07	Lantern Pharma Inc.(NasdaqCM:LTRN) dropped from Russell Microcap Value Index	CI
01/07	Lantern Pharma Inc.(NasdaqCM:LTRN) dropped from Russell 3000E Value Index	CI

Lantern Pharma Inc.(NasdaqCM:LTRN) dropped from Russell 3000E Value Index

July 01, 2024

Latest news about Lantern Pharma Inc.

Lantern Pharma Inc.(NasdaqCM:LTRN) dropped from Russell Microcap Value Index	01/07	CI
Lantern Pharma Inc.(NasdaqCM:LTRN) dropped from Russell 3000E Value Index	01/07	CI
Lantern Pharma Secures Composition of Matter Patent for LP-284 in Japan	12/06	MT
Lantern Pharma Inc. Receives Certificate of Patent from Japanese Patent Office for Composition of Matter Covering Drug Candidate LP-284	12/06	CI
Transcript : Lantern Pharma Inc. - Special Call	29/05
Lantern Pharma Files $150 Million Mixed Shelf	25/05	MT
Transcript : Lantern Pharma Inc., Q1 2024 Earnings Call, May 09, 2024	10/05
Lantern Pharma Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	10/05	CI
Lantern Pharma, Oregon Therapeutics Partner to Develop AI-Driven Cancer Drug Collaboration	06/05	MT
Lantern Pharma Inc. Announces A Strategic AI-Driven Collaboration with Oregon Therapeutics to Optimize the Development of its First-In-Class Protein Disulfide Isomerase Inhibitor Drug Candidate XCE853 in Novel and Targeted Cancer Indications	06/05	CI
Transcript : Lantern Pharma Inc. - Special Call	24/04
Lantern Gets Regulatory Approval in Japan, Taiwan for Non-Small Cell Lung Cancer Trial Expansion	22/04	MT
Lantern Pharma Inc. Receives Regulatory Approval to Expand Harmonic Clinical Trial for Non-Small Cell Lung Cancer in Never-Smakers into Japan and Taiwan	22/04	CI
Transcript : Lantern Pharma Inc., Q4 2023 Earnings Call, Mar 18, 2024	19/03
Lantern Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	19/03	CI
Lantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, Lp-284	15/03	CI
Lantern Pharma Inc. Announces Series of Important Milestones Related to the Development, Size, and Advancement of RADR	04/03	CI
Lantern Pharma Advances Unique ADC Program Across Multiple Solid Tumor Cancers	15/02	CI
Transcript : Lantern Pharma Inc., Q3 2023 Earnings Call, Nov 08, 2023	09/11
Lantern Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11	CI
Lantern Pharma Inc. Announces the Death of Dr. Franklyn Prendergast, a Director of the Company	21/23/21	CI
Lantern Pharma Inc. Announces Publication in Clinical Cancer Research Highlighting the Enhanced Efficacy of Lp-184 in Glioblastoma	03/23/03	CI
Lantern Pharma Doses First Patient in Phase 1 Trial of Advanced Solid Tumor Drug Candidate	25/23/25	MT
Lantern Pharma Inc. Announces First Patient Dosed in the Phase 1 Study for LP-184 in Advanced Solid Tumors	25/23/25	CI
Sector Update: Health Care Stocks Mixed Monday Afternoon	18/23/18	MT

Lantern Pharma Inc. is an artificial intelligence (AI) company. The Company is developing targeted and transformative cancer therapies using its proprietary RADR AI and machine learning (ML) platform with multiple clinical-stage drug programs. Its proprietary AI and machine learning (ML) platform, RADR, leverages over 60 billion oncology-focused data points and a library of over 200 advanced ML algorithms to help solve problems in oncology drug development. It is engaged in the development of its pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody drug conjugate (ADC) program. It has active clinical programs for its three lead small molecule drug candidates: LP-300, LP-184, and LP-284. These programs are focused on multiple cancer indications, including both solid tumors and blood cancers. It is also focused on the clinical execution of its therapies for CNS and brain cancers through Starlight Therapeutics Inc.

Sector

Biotechnology & Medical Research

Calendar

06/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.38 USD

Average target price

22 USD

Spread / Average Target

+402.28%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
LANTERN PHARMA INC.	+2.34%	47.12M
MODERNA, INC.	+18.97%	45.34B
LONZA GROUP AG	+41.98%	40.42B
IQVIA HOLDINGS INC.	-10.06%	37.92B
ALNYLAM PHARMACEUTICALS, INC.	+31.15%	31.75B
CELLTRION, INC.	-7.79%	27.71B
ICON PUBLIC LIMITED COMPANY	+13.32%	26.52B
UNITED THERAPEUTICS CORPORATION	+43.05%	13.96B
MEDPACE HOLDINGS, INC.	+31.28%	12.44B
BIO-TECHNE CORPORATION	-7.41%	11.26B

Other Biotechnology & Medical Research